Because mScarb2-reactive CD8+ T cells recognized YTN16, and mCdt1- and mZfp106-reactive CD8+ T cells responded to YTN2 and YTN16 cells in vitro and in vivo (Figure 3 and Figure 7), these cancer cells indeed presented these neoepitope peptide/MHC class I complexes on their surface. Here, CD8A is linked to cancer.